Liftstream is an executive search recruitment company in the life sciences sector
Liftstream Attending World Orphan Drug Congress in Geneva
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Cydan, David Mott, Duchenne Muscular Dystrophy, funding, Liftstream, NEA, Orphan drugs, Prosensa, PTC Therapeutics, public private funding, Rare Disease, Sarepta, Shire, Summit, venture capital, Viropharma, WODC, world orphan drug congress
Leave a comment
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abingworth Management, BioPharma America, Biotechnology cluster, Boston, Brookside Capital, Cristina Csimma, Cydan, David Mott, Deerfield, DELPHI, Dicer Substrate siRNA, Dicerna Pharmaceuticals, drug delivery technologies, Duchenne Muscular Dystrophy, EDI200, Edimer Pharmaceuticals, EnCore™, exon skipping, Exportin-1, Forsite Capital Management, Genzyme, Inhibitors of Nuclear Export, innovation, investors, Karyopharm Therapeutics, Massachusetts, Neil Kirby, New Enterprise Associates, New Leaf Venture Partners, NEZ, Omega Funds, oncology market, Orphan Drug, Prosensa, RA Capital, Rare Disease, Sanofi, Series B, SR One, Third Rock Ventures, TKT, undruggable disease, Vertex Pharmaceuticals, X-linked Hypohidrotic Ectodermal Dysplasia, XLHED
Leave a comment
David Motts’ NEA weighs in on rare diseases
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged AstraZeneca, Cambridge MA, Clarus Ventures, Cydan, David Mott, DMD, Dr. Cristina Csimma, Duchenne Muscular Dystrophy, GSK, International Rare Diseases Research Consortium, James McArthur, MedImmune, NEA, Orphan Drug, orphan drug accelerator, Prosensa, Rare Disease, Treat-NMD, Virdante Pharmaceuticals, Wyeth
Leave a comment
It’s as simple as ADC for Mersana Therapeutics
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC, American Association for Cancer Researc, Antibody-drug conjugates, David Mott, Endo Pharmaceuticals, Fidelity Biosciences, Immunogen, Mersana Therapeutics, NEA, New Enterprise Associates, Pfizer Venture Fund, PureTech Ventures, Roche, seattle genetics, Timothy B. Lowinger, Washington
Leave a comment
Prosensa & GSK pool resources to drive Drisapersen in Duchenne
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases
Tagged Abingworth, David Mott, DMD, Drisapersen, Duchenne, Dystrophin, Exon 51, Genzyme, GSK, GSK’s Centre of Excellence for External Drug Discovery, Hans Schikan, Henri Termeer, Huntington's, Leiden University Medical Center, Massachusetts, MedImmune, mRNA, New Enterprise Associates (NEA), Phase II, PRO051, Prosensa, The New England Journal of Medicine
Leave a comment
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abbott, AbbVie, Amgen, Angus Russell, AstraZeneca, Bluebird bio, Cancer Vaccine, CEO, Cystic Fibrosis, Dalvir Gill, David Mott, Director General EFPIA, EFPIA, EMEA, Erbitux, FDA, Flemming Ornskov, Foundation Medicine, FoundationOne, Gattex, Gene therapy, Gilead Sciences, Glybera, HCV, Hepatitis, Humira, INSPIRE, Jeff Leiden, Jeremy Levin, John Martin, Kalydeco, Karl-Ludwig Kley, Lotus Tissue Repair, Merck KGaA, Michael Pellini, Natpara, New Enterprise Associates, NP Pharmaceuticals, oncology, Orphan drugs, Pascal Soriot, rare diseases, Richard Bergstrom, Richard Gonzalez, Shire, Shire Speciality pharma, Sofosbuvir, Stimuvax, Takeda, Teva, TransCelerate, Ultragenyx, uniQure, Vertex Pharmaceuticals, Vyvanse
Leave a comment